Ion Channel Therapeutics for Pain

Overview

Journal Channels (Austin)

Specialty Biochemistry

Date 2015 Jul 29

PMID 26218246

Citations 17

Authors

Sarah E Skerratt

Christopher W West

Affiliations

Soon will be listed here.

Abstract

Pain is a complex disease which can progress into a debilitating condition. The effective treatment of pain remains a challenge as current therapies often lack the desired level of efficacy or tolerability. One therapeutic avenue, the modulation of ion channel signaling by small molecules, has shown the ability to treat pain. However, of the 215 ion channels that exist in the human genome, with 85 ion channels having a strong literature link to pain, only a small number of these channels have been successfully drugged for pain. The focus of future research will be to fully explore the possibilities surrounding these unexplored ion channels. Toward this end, a greater understanding of ion channel modulation will be the greatest tool we have in developing the next generation of drugs for the treatment of pain.

Citing Articles

Phytochemical-based therapeutics from traditional eastern medicine: analgesic effects and ion channel modulation.

Kim S, Chung G, Kim S Front Pain Res (Lausanne). 2025; 6:1537154.

PMID: 39958366 PMC: 11825757. DOI: 10.3389/fpain.2025.1537154.

Effects of carbamazepine on BDNF expression in trigeminal ganglia and serum in rats with trigeminal neuralgia.

Song Y, Zhou M, Xiong J, Huang R, Shen W, Zhan T Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(1):11-20.

PMID: 38615161 PMC: 11017024. DOI: 10.11817/j.issn.1672-7347.2024.230278.

Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China.

Ma K, Cheng Z, Jiang H, Lin Z, Liu C, Liu X J Pain Res. 2024; 17:953-963.

PMID: 38476873 PMC: 10929561. DOI: 10.2147/JPR.S445171.

Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression.

Bahcheli A, Min H, Bayati M, Zhao H, Fortuna A, Dong W EMBO J. 2024; 43(2):196-224.

PMID: 38177502 PMC: 10897389. DOI: 10.1038/s44318-023-00016-x.

Plant-derived natural products targeting ion channels for pain.

Goyal S, Goyal S, Goins A, Alles S Neurobiol Pain. 2023; 13:100128.

PMID: 37151956 PMC: 10160805. DOI: 10.1016/j.ynpai.2023.100128.

References

Altier C, Dale C, Kisilevsky A, Chapman K, Castiglioni A, Matthews E . Differential role of N-type calcium channel splice isoforms in pain. J Neurosci. 2007; 27(24):6363-73. PMC: 6672448. DOI: 10.1523/JNEUROSCI.0307-07.2007. View

Keystone E, Wang M, Layton M, Hollis S, McInnes I . Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012; 71(10):1630-5. DOI: 10.1136/annrheumdis-2011-143578. View

Vincent F, Acevedo A, Nguyen M, Dourado M, DeFalco J, Gustafson A . Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009; 389(3):490-4. DOI: 10.1016/j.bbrc.2009.09.007. View

Bowie D . Ionotropic glutamate receptors & CNS disorders. CNS Neurol Disord Drug Targets. 2008; 7(2):129-43. PMC: 2662616. DOI: 10.2174/187152708784083821. View

Andrews M, Af Forselles K, Beaumont K, Galan S, Glossop P, Grenie M . Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain. ACS Med Chem Lett. 2015; 6(4):419-24. PMC: 4394344. DOI: 10.1021/ml500479v. View

Khakh B, North R . P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006; 442(7102):527-32. DOI: 10.1038/nature04886. View

Rami H, Thompson M, Stemp G, Fell S, Jerman J, Stevens A . Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006; 16(12):3287-91. DOI: 10.1016/j.bmcl.2006.03.030. View

Xiong Z, Strichartz G . Inhibition by local anesthetics of Ca2+ channels in rat anterior pituitary cells. Eur J Pharmacol. 1999; 363(1):81-90. DOI: 10.1016/s0014-2999(98)00769-9. View

Yang W, Levesque P, Little W, Conder M, Ramakrishnan P, Neubauer M . Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem. 1998; 273(31):19419-23. DOI: 10.1074/jbc.273.31.19419. View

10.

Silverman R . From basic science to blockbuster drug: the discovery of Lyrica. Angew Chem Int Ed Engl. 2008; 47(19):3500-4. DOI: 10.1002/anie.200704280. View

11.

Scanio M, Shi L, Drizin I, Gregg R, Atkinson R, Thomas J . Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain. Bioorg Med Chem. 2010; 18(22):7816-25. DOI: 10.1016/j.bmc.2010.09.057. View

12.

Mruk K, Kobertz W . Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes. PLoS One. 2009; 4(1):e4236. PMC: 2617778. DOI: 10.1371/journal.pone.0004236. View

13.

Chenard B, Bordner J, Butler T, Chambers L, Collins M, De Costa D . (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem. 1995; 38(16):3138-45. DOI: 10.1021/jm00016a017. View

14.

Kremeyer B, Lopera F, Cox J, Momin A, Rugiero F, Marsh S . A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010; 66(5):671-80. PMC: 4769261. DOI: 10.1016/j.neuron.2010.04.030. View

15.

Guile S, Ince F, Ingall A, Kindon N, Meghani P, Mortimore M . The medicinal chemistry of the P2 receptor family. Prog Med Chem. 2002; 38:115-87. DOI: 10.1016/s0079-6468(08)70093-6. View

16.

Yamamoto T, Takahara A . Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009; 9(4):377-95. DOI: 10.2174/156802609788317838. View

17.

Blackburn-Munro G, Jensen B . The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol. 2003; 460(2-3):109-16. DOI: 10.1016/s0014-2999(02)02924-2. View

18.

Kemp M . Structural trends among second-generation voltage-gated sodium channel blockers. Prog Med Chem. 2010; 49:81-111. DOI: 10.1016/S0079-6468(10)49003-7. View

19.

Gogas K . Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol. 2005; 6(1):68-74. DOI: 10.1016/j.coph.2005.11.001. View

20.

Lloyd R, BLYTHE Jr J . Clinical experiences with lidocaine as a local anesthetic. J Am Dent Assoc. 1949; 39(3):296-8. DOI: 10.14219/jada.archive.1949.0206. View